Sareum Holdings plc today announced its audited results for the year ended 30 June 2022. The operating loss of £2.6m and the cash balance of £4.3m were in line with our forecasts. We maintain our June 23 forecasts for the P&L but have updated the balance sheet and cash flow numbers, positively, mainly to reflect the better cash balance at 30 June 2022.
SDC-1801 (autoimmune disease): SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic with an initial focus on psoria ....
24 Oct 2022
Hybridan Research: 24/10/2022: Sareum Holdings plc: Annual Results: SDC-1801 and SDC-1802 in progress and SRA737 under strategic review
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hybridan Research: 24/10/2022: Sareum Holdings plc: Annual Results: SDC-1801 and SDC-1802 in progress and SRA737 under strategic review
Sareum Holdings plc (SAR:LON) | 11.0 -0.4 (-24.1%) | Mkt Cap: 7.89m
- Published:
24 Oct 2022 -
Author:
Emily Liu -
Pages:
9
Sareum Holdings plc today announced its audited results for the year ended 30 June 2022. The operating loss of £2.6m and the cash balance of £4.3m were in line with our forecasts. We maintain our June 23 forecasts for the P&L but have updated the balance sheet and cash flow numbers, positively, mainly to reflect the better cash balance at 30 June 2022.
SDC-1801 (autoimmune disease): SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic with an initial focus on psoria ....